# Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

> **NCT02499835** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 66 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Soft Tissues
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** pTVG-HP Plasmid DNA Vaccine

## Key facts

- **NCT ID:** NCT02499835
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2021-08-09
- **Final completion:** 2023-07-27
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499835, "Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02499835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*